establish highli
competit wall data
keytruda sale lynparza/lenvima allianc revenu
mrk investor event re-affirmed keytruda leadership posit nsclc
data establish wall data sizabl lead io
competitor rais keytruda out-year sale
vs street sinc apr driven nsclc lower
opdivo sale lynparza/lenvima allianc revenu
vs street offer diversif combo leverag similar deal
expect data evolv oncolog sale drive growth/margin expans
reiter buy rais pt ep
keytruda sale rais breath/depth lung data
host investor event discuss data present american
societi clinic oncolog meet chicago think breadth
 depth keytruda data establish high barrier entri wall
data especi nsclc result rais keytruda sale
us ex-u vs street us
ex-u global april lower opdivo
sale click note titl opdivo sale lower nsclc
competit pt addit partner astrazeneca
azn rate eisai rate present posit lynparza
combo data breast cancer lenvima combo data renal cell carcinoma
click note titl keytruda shine nsclc lynparza/lenvima
add diversif allianc revenu support consensu
estim mrk allianc revenu out-year vs
street note previous click note titl oncolog
vaccin ah account sale drive om expans
allianc revenu estim along gener mix-shift toward specialti
sale drive signific margin expans out-year offset pressur
declin hcv segment januvia us loss-of-exclus
conserv model oper margin
contribut ep compound-annual-growth-rate vs street
materi sale compound-annual-growth-rate vs street reiter buy
rais pt assum trade ep
larg driven best-in-class oncolog franchis support dcf risk
includ regulatori commerci challeng new product launch clinic
tr target
keytruda posit domin nsclc wall data
mrk domin posit first-lin non-smal cell lung cancer nsclc market support
anoth set robust data read-out note previous click mrk
data show keytruda monotherapi provid surviv benefit across
squamou sq /non-squam nsq nsclc patient express although
see import driver keytruda sale lung cancer hand mrk
data click note provid global access non-
squamou patient file review us/eu/jp data click
note solidifi keytruda posit squamou give keytruda access combin
nsclc market mrk nsclc posit improv roch rog-ch
rate report underwhelm tecentriq avastin chemo non-sq nsclc os
 tecentriq chemo sq nsclc data bristol-my
buy nsclc strategi focus tmb-high low patient
market global lung market model assum opdivo io-nav nsclc patient popul
begin shrink acceler rate near-term mostli driven keytruda uptak nsclc
expect market nave
outsid nsclc mrk sclc data bode well data
 think repres underappreci opportun keytruda adjuvant/
neoadjuv tnbc mrk investor present compani highlight trial read-out
three expect fda regulatori action outsid lung cancer next month
think drive keytruda sale growth model keytruda sale vs street
april
note click mrk partner azn lynparza eisai lenvima present posit data
respect asset week provid support above-consensu allianc
revenu estim asset out-year view wise use balanc
sheet past month add asset oncolog pipelin opportun
diversifi oncolog sale also bolster keytruda sale ration clinic meaning
combin strategi expect continu use balanc sheet pursu addit
busi develop deal next year scienc around io-resist evolv
leverag keytruda posit clinic partner-of-choic next-gener oncolog
asset model allianc revenu materi street
keytruda data solid sclc esp patient
monday june present result keytruda monotherapi
treatment-experienc small cell lung cancer sclc patient regardless express
compar data abstract data sclc cohort bmi
trial opdivo yervoy click postview in-depth
analysi data see exhibit cross-trial analysi given small patient number
trial control arm draw firm conclus cross-trial analysi
think keytruda opdivo perform fairli compar given differ patient characterist pd-
statu line therapi overal think keytruda clinic activ sclc difficult-to-treat
tumor type solid warrant investig particularli patient
efficaci evalu intent-to-treat patient keytruda object respons rate
vs opdivo pool random non-random cohort
opdivo yervoy keytruda orr meaning higher patient evalu
 vs evalu opdivo yervoy exhibit typic
relationship statu respons non-random cohort think
like statist aberr caus low number patient arm
evalu opdivo opdivo yervoy breadth respons
keytruda opdivo yervoy overwhelm difficult-to-treat tumor type patient
experi tumor shrinkag tend durabl respons think led robust
surviv result single-arm trial would typic expect base orr data
think encourag prospect see surviv benefit larger studi sclc
tumor type standard-of-car often defin respons limit durabl particularli
page
later line therapi median durat respons mdor keytruda reach rang
month median follow-up month respond dor
mdor rang month surviv keytruda median progress free surviv
month rate patient perform meaning
better patient month vs
month patient keytruda show median overal surviv mo
month vs month opdivo/opdivo yervoy non-random cohort evalu
keytruda patient perform meaning better patient
mo impress month vs month safeti keytruda
perform in-lin monotherapi trial patient experienc treatment-rel
advers event trae grade trae two treatment-rel patient death
bode well behind sclc
base data think keytruda monotherapi clinic activ sclc particularli
patient patient respond treatment appear deriv
meaning durabl benefit result add confid data mrk
trial evalu keytruda chemo etoposid carboplatin/cisplatin vs chemo
sclc expect data data posit keytruda chemo could
market sclc assum prioriti review howev remind bmi opdivo
expect sclc market aug pdufa expect two sclc
read-out opdivo opdivo yervoy mainten
roch similar regimen tecentriq etoposid
carboplatin sclc expect read-out next week even posit
data may end third sclc market could limit sclc commerci
opportun keytruda despit domin leadership posit nsclc
tnbc data materi catalyst
mrk investor present highlight oncolog trial read-out across eight tumor
type next month trial one think underappreci street
phase trial evalu keytruda vs placebo neoadjuv adjuv
treatment patient local advanc tripl neg breast cancer tnbc expect
read-out present trial design poster abstract
enrol on-going countri site global goal tnbc patient enrol
accord clinicaltri gov think high probabl success base robust
efficaci keytruda neoadjuv tnbc i-spi remind i-spi data present
show patholog complet respons pcr rate keytruda neoadjuv tnbc
vs standard-of-car chemo mostli line data
pcr also present click note data robust
expect adjuvant/neoadjuv tnbc could meaning commerci opportun keytruda
breast cancer largest tumor type annual incid us new case per
year accord american cancer societi tnbc repres case accord
scientif literatur new case annual us make tnbc tumor type
roughli similar size hepatocellular carcinoma market one-half size
melanoma howev unlik melanoma littl io competit early-lin tnbc
therapi agent current approv tnbc line therapi roch
robust tnbc develop plan six on-going tecentriq trial adjuvant/neoadjuv
metastat set roch expect data studi begin howev apart
tecentriq player far behind bmy/azn on-going trial
tnbc opdivo/imfinzi hold merck kgaa mrk-de rate tnbc trial
bavencio a-brav expect read-out accord clinicaltri gov
data secur monopoli posit tnbc even duopoli roch think
could repres global upsid keytruda outsid lung cancer
keytruda data nsclc brain met show efficaci
keytruda becom standard-of-car nsclc think import asset continu
show benefit chemo difficult treat nsclc patient includ metastas
less known io therapi fortun investig present encourag phase
data keytruda monotherapi nsclc patient activ asymptomat brain metastas
page
keytruda-tr patient studi divid mostli evenli line therapi patient
efficaci patient
patient discord system respons four patient
progress diseas pd brain partial respons pr bodi three patient
pr brain pd bodi among patient respons stabl diseas
month patient unevalu none patient report brm
respons although two patient live year median os across patient
month two-year os safeti keytruda monotherapi well-toler
neurolog trae grade investig conclud pembrolizumab result durabl
benefit long-term surviv patient untreat brm nsclc inhibitor
activ may safe activ treatment option patient small
asymptomat brm note keytruda becom standard-of-car nsclc think read-
out like one overli meaning add grow mountain
data support use keytruda nsclc
page
exhibit present
phase studi carboplatin-paclitaxel/nab-paclitaxel chemo
without pembrolizumab pembro patient pt
rais bar
chemo first-lin therapi advanced/metastat nsclc
phase studi
niraparib pembrolizumab patient pt advanc
tripleneg breast cancer recurr ovarian cancer
roc result roc cohort
alon patient pt unresect metastat melanoma
result phase studi
phase ii open-label multi-centr studi bemcentinib
first-in-class select inhibitor combin
pembrolizumab patient advanc nsclc
pembrolizumab pembro vs paclitaxel ptx previous treat
advanc gastric gastroesophag junction g/gej cancer
pembrolizumab monotherapi first-lin therapi advanc clear
cell renal cell carcinoma accrcc result cohort
phase studi pembrolizumab advanc small-cel lung cancer
overal surviv cohort
pemetrexed-carboplatin plu pembrolizumab first-lin therapi
advanc nonsquam nsclc
efficaci safeti entinostat ent pembrolizumab
pembro patient melanoma progress pd-
olaparib combin abirateron patient pt
niraparib pembrolizumab patient pt
metastat triple-neg breast cancer tnbc phase
rais bar
rais bar
pegilodecakin nivolumab nivo pembrolizumab pembro
patient pt metastat renal cell carcinoma rcc
updat efficaci safeti statu patient hr
phase ii studi pembrolizumab egfr-mut
tyrosin kinas inhibitor tki nave patient advanc nsclc
phase random studi pembrolizumab pembro plu
lenalidomid len low-dos dexamethason rd versu rd
newli diagnos treatment-na multipl myeloma mm
phase random studi pembrolizumab pembro plu
pomalidomid pom dexamethason
strh research import present highlight blue color import present highlight grey
page
exhibit present cont
investig express respons pembrolizumab
pembro gastric cancer gc cervic cancer cc use
combin posit score tumor proport score tp
first-in-human phase studi anti-human
monoclon antibodi monotherapi combin
pembrolizumab patient advanc solid tumor
safeti efficaci pembrolizumab pembro plu capecitabin
cape metastat tripl neg breast cancer mtnbc
phase ii singl arm studi assess efficaci
pembrolizumab pembro plu radiotherapi rt metastat
phase ii trial pembrolizumab metastat cutan
random phase ib/ii studi select small molecul axl
inhibitor bemcentinib combin either
dabrafenib/trametinib pembrolizumab patient
random phase ii studi pembrolizumab stereotact
bodi radiotherapi sbrt versu pembrolizumab alon patient
advanc non-smal cell lung cancer pembro-rt studi
overal surviv patient advanc nsclc treat
pembrolizumab result
efficaci safeti entinostat ent pembrolizumab
pembro patient non-smal cell lung cancer nsclc
previous treat therapi
translat research
head neck cancer
safeti efficaci combin olaparib temozolomid
small cell lung cancer sclc
pembrolizumab combin cetuximab patient
recurrent/metastat r/m head neck squamou cell
carcinoma hnscc result interim safeti analysi
docetaxel vinflunin recurr advanc urotheli cancer
uc follow-up phase trial
updat efficaci safeti single-arm phase
studi investig first-lin pembrolizumab pembro
immun profil random phase ii trial acalabrutinib
pembrolizumab pa versu pembrolizumab patient
phase ib phase ii studi pembrolizumab
bevacizumab treatment metastat renal cell
lenvatinib pembrolizumab patient renal cell carcinoma
pembrolizumab pembro docetaxel-refractori
adxs-psa plu pembrolizumab pembro
pembrolizumab pembro plu enzalutamid metastat
castrat resist prostat cancer mcrpc extend follow
strh research import present highlight blue color import present highlight grey
page
exhibit present cont
phase trial olaparib parp inhibitor vistusertib
inhibitor recurr endometri ovarian tripl neg
antitumor activ safeti pembrolizumab patient
advanc recurr ovarian cancer interim result phase
pembrolizumab treatment advanc cervic cancer updat
result phase studi
lenvatinib pembrolizumab patient advanc endometri
phase trial lenvatinib plu pembrolizumab patient
squamou cell carcinoma head neck
phase ii studi pembrolizumab pembrolizumab plu
bevacizumab recurr glioblastoma rgbm patient
pembrolizumab patient advanc
encor phase studi entinostat combin
pembrolizumab patient microsatellit stabl metastat
pembrolizumab pembro patient advanc hepatocellular
margetuximab plu pembrolizumab
pembrolizumab patient previous treat metastat
adenocarcinoma squamou cell carcinoma esophagu
head neck cancer
platinum-bas chemotherapi periop pembrolizumab
placebo resect stage iib iiia nsclc
strh research import present highlight blue color import present highlight grey
page
exhibit cross trial analysi keytruda vs opdivo yervoy sclc vs
keytruda opdivo sclc
page
number patient random
men patient
prior line therapi
prior line
number efficacy-evalu patient
orr patient
durat repons dor
patient
patient
patient
patient
random cohort data avail non-random cohort
non-random cohort data avail random cohort
one patient neoadjuvant/adjuv prior therapi
pool data random non-random cohort
exhibit cross trial analysi keytruda vs opdivo yervoy sclc cont
keytruda opdivo sclc
number patient
orr patient
patient
os patient
number patient
orr patient
patient
os patient
number treat patient
trae grade treat patient
trae lead discontinu
trae lead death patient
non-random cohort data avail random cohort
one patient neoadjuvant/adjuv prior therapi
pool data random non-random cohort
treatment relat death due pneumonia one due encephalopathi
treatment relat death due pneumon
treatment relat death due pneumon one due myasthenia gravi one due seizures/enceph one due
page
exhibit estim strh vs consensu us million expect ep
page
page
page
page
materi product
depreci
equival
prepaid expens tax
net properti plant equip
loan payabl current portion lt debt
defer incom tax non-current liabil
accumul comprehens incom
total sharehold equiti liabil
page
exhibit statement flow
depreci amort
chang work capit
oper
purchas secur invest
sale secur invest
proce sale busi
acquisit busi
invest
chang short-term debt
proce issuanc lt debt
payment long term debt
purchas treasuri stock
proce stock option
financ
effect exchang rate
cash/equival begin period
cash/equival end period
page
merck co inc commit premier research-intens biopharmaceut
compani strategi discov develop provid innov product servic save
improv live around world innov medicin vaccin anim health product
gener us ex-u total revenu merck core area
focu oncolog diabet virolog vaccin account
sale respect sever key brand product oncolog keytruda diabet januvia/janumet/
marizev japan vaccin gardasil drive growth addit growth opportun
immunolog women hospital/acut along grow biosimilar portfolio mrk
anim busi yield sale repres total sale
rate buy key global leader immuno-oncolog io market flagship
asset keytruda establish foundat io asset approv favor clinic data
multipl tumor type keytruda earlier expect posit result non-smal cell lung cancer
nsclc sourc upsid allow maintain first-mov advantag import
think one broadest clinic trial program
trial tumor type along combin trial sinc septemb keytruda
approv key indic us also grant number
breakthrough therapi design keytruda domin io market wall-of-data
extend mrk collabor astrazeneca lynparza parp deal
diabet mrk januvia/janumet franchis pressur type diabet market move
away toward newer effect agent like growth
mrk diabet franchis expect come inhibitor steglatro ertugliflozin
weekli marizev launch japan insulin conjug expect
launch
outsid oncolog anim health continu show strong growth think mrk
franchis consider competit pressur signific pressur come
virolog busi also see modest downward pressur mrk vaccin busi
zostavax face competit glaxosmithklin shingrix gardasil expect declin
us/eu due adopt two dose regimen vs previou three dose
model sales/ep cagr vs street
valuat risk
target price assum merck trade ep estim support
discount cash flow dcf model multipl ep group averag
think appropri given mrk leadership immuno-oncolog space
keytruda first-mov advantag nsclc
risk rate target price includ failur capit truda first-mov advantag
nsclc approv use januvia franchis see materi declin sale due rise
competit oral dpp-iv segment clinic regulatori risk keytruda
relebactam infect herp zoster valent pneumococc vaccin
global price risk invest risk relat biopharmaceut industri includ global price risk
payer polit risk clinic develop risk regulatori risk commerci risk legal
risk patent challeng
page
compani mention note
astrazeneca plc azn rate
eisai co ltd rate
merck kgaa mrk-de rate
roch hold ltd genusssch rog-ch rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
